HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $90 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Arrowhead Pharma (NASDAQ:ARWR) and maintained a $90 price target.
June 30, 2023 | 10:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arrowhead Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $90.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $90 indicates the firm's continued confidence in the company's potential. This could lead to increased investor confidence and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100